- Home
- PTA vs PCRX Comparison
PTA vs PCRX Comparison
Compare PTA & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PTA | PCRX |
|---|---|---|
| Founded | 2020 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 999.0M |
| IPO Year | N/A | 2010 |
Fundamental Metrics
Financial Performance| Metric | PTA | PCRX |
|---|---|---|
| Price | $19.14 | $25.72 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $30.25 |
| AVG Volume (30 Days) | 105.1K | ★ 448.9K |
| Earning Date | 01-01-0001 | 04-30-2026 |
| Dividend Yield | ★ 8.31% | N/A |
| EPS Growth | N/A | ★ 107.44 |
| EPS | N/A | ★ 0.07 |
| Revenue | N/A | ★ $541,533,000.00 |
| Revenue This Year | N/A | $6.78 |
| Revenue Next Year | N/A | $8.54 |
| P/E Ratio | ★ N/A | $362.14 |
| Revenue Growth | N/A | ★ 26.04 |
| 52 Week Low | $18.13 | $18.80 |
| 52 Week High | $20.92 | $27.64 |
Technical Indicators
Market Signals| Indicator | PTA | PCRX |
|---|---|---|
| Relative Strength Index (RSI) | 44.43 | 62.25 |
| Support Level | $19.02 | $21.89 |
| Resistance Level | $19.57 | $26.94 |
| Average True Range (ATR) | 0.20 | 0.89 |
| MACD | -0.02 | -0.03 |
| Stochastic Oscillator | 32.20 | 58.30 |
Price Performance
Historical ComparisonAbout PTA Cohen & Steers Tax-Advantaged Preferred Securities and Income Fund of Beneficial Interest
COHEN & STEERS TAX-ADV PRD SEC AND INC is a non-diversified, closed-end management statutory trust. Its main investment objective is high current income, and the Fund's secondary investment objective is capital appreciation.
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.